NCT06710132

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2025-01-29Est. Completion: 2027-12-23

Enrollment target: 250 participants

Locations

University of California - Los Angeles - 300208353, Santa Monica, California, United States
Providence Medical Foundation, Santa Rosa, California, United States
Georgetown University - Lombardi Comprehensive Cancer Center - 1134847, Washington D.C., District of Columbia, United States
D&H Cancer Research Center, Margate, Florida, United States
Prisma Health Cancer Institute, ITOR, CRU, Greenville, South Carolina, United States
Baptist Cancer Center, Memphis, Tennessee, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
NEXT Virginia, Fairfax, Virginia, United States
Flinders Medical Centre, Bedford Park, Australia
Nepean Cancer Care Centre, Kingswood, Australia
Mater Misericordiae Ltd - PARENT, South Brisbane, Australia
Macquarie University Hospital - PARENT, Sydney, Australia
Ordensklinikum Linz Krankenhaus der Elisabethinen Linz - Pneumology, Linz, Austria
LKH - Universitätsklinikum der PMU Salzburg - Innere Med III/Hämatologie und Onkologie, Salzburg, Austria
Medical University of Vienna - Department of Internal Medicine, Vienna, Austria

EGFR OverexpressionLocally Advanced Solid TumorMetastatic Solid Tumor

This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Ad…

Seoul, South KoreaEst. completion Jun 2027

Recurrent Melanoma (Skin)Metastatic MelanomaMelanoma Stage IVMelanoma Stage III

In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therape…

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.